Stonegate updates IXHL coverage as IHL-42X advances from regulatory prep to active execution, with first-patient dosing underway. The DReAMzz trial targets ~120 patients across nine dose combinations at 14 U.S. sites, aiming for mid-2027 completion. IXHL holds $68.4 million in unrestricted cash, providing about 12 months of runway, but long-term funding remains likely, shifting focus to dose optimization and Phase 3 design rather than immediate profitability.
Incannex Healthcare is set to raise approximately $10 million from institutional investors through the sale of 2 million shares and accompanying warrants. This funding is pivotal for advancing the Phase 2 clinical trial of its lead candidate, IHL-42X, which targets obstructive sleep apnea, and it positions the company for further growth with anticipated Phase 3 studies starting in late 2027.
Incannex announced positive Phase 2 trial results for IHL-42X treatment. Significant AHI reductions achieved: 83% in high-dose, 79% in low-dose IHL-42X. Patient-reported outcomes show improvement in sleep-related impairments. IHL-42X well tolerated with mild or moderate side effects reported. IXHL stock rose 24.3% following the announcement.
